Hiroki Saito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hiroki Saito has a total of 230 co-authors. Here are the top co-authors by number of shared publications:
- Shigeki Fujitani
Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Kanagawa, Japan
4 shared publications - Haruaki Wakatake
Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8511, Kanagawa, Japan
3 shared publications Kazuaki Jindai
Department of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan
3 shared publicationsAbigail Beane
2 shared publications- Aidan Burrell
Intensive Care Medicine (A.B.), The Alfred Hospital, Melbourne, VIC, Australia
2 shared publications - Alistair Nichol
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia
2 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Elsevier in CMI Communications
- Vol. 3 (4)
Eritoran and apremilast in hospitalized patients with COVID-19: The REMAP-CAP immune modulation-2 domain
- 15 September 2026
- Published by Elsevier in CMI Communications
- Vol. 3 (4)
Open AccessEritoran and apremilast in hospitalized patients with COVID-19: The REMAP-CAP immune modulation-2 domain
- Open Access
- 13 March 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
A scoping review of randomized controlled trials in the early phase of the COVID-19 pandemic: country-level research response to COVID-19 therapeutics and vaccines
Clinical trials are central in pandemic preparedness and response (PPR). This scoping review aimed to illustrate the landscape of COVID-19-related randomiz
- 13 March 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessA scoping review of randomized controlled trials in the early phase of the COVID-19 pandemic: country-level research response to COVID-19 therapeutics and vaccines
Clinical trials are central in pandemic preparedness and response (PPR). This scoping review aimed to illustrate the landscape of COVID-19-related randomiz
- Open Access
- 11 March 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Views on consent approaches used in emergency and critical care research: a rapid, systematic review
Obtaining informed consent can be challenging in emergency and critical care research due to the acute and severe nature of the patient’s condition.
- 11 March 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Open AccessViews on consent approaches used in emergency and critical care research: a rapid, systematic review
Obtaining informed consent can be challenging in emergency and critical care research due to the acute and severe nature of the patient’s condition.
- Open Access
- 23 February 2026
- Published by Springer Nature in BMC Medical Ethics
- Vol. 27 (1)
What did trial participants in REMAP-CAP Japan experience during the COVID-19 pandemic? A qualitative study
Informed consent is crucial for clinical trial participation. However, there have been no qualitative studies of participants’ experiences in randomi
- 23 February 2026
- Published by Springer Nature in BMC Medical Ethics
- Vol. 27 (1)
Open AccessWhat did trial participants in REMAP-CAP Japan experience during the COVID-19 pandemic? A qualitative study
Informed consent is crucial for clinical trial participation. However, there have been no qualitative studies of participants’ experiences in randomi
- 3 December 2025
- Published by Elsevier in Journal of Hospital Infection
- Vol. 171, 171-173
First Train-the-Trainers in Hand Hygiene in Uganda: a multilevel evaluation
- 3 December 2025
- Published by Elsevier in Journal of Hospital Infection
- Vol. 171, 171-173
First Train-the-Trainers in Hand Hygiene in Uganda: a multilevel evaluation
- Open Access
- 1 July 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-43
Building an international precision medicine platform trial for the acute respiratory distress syndrome (ARDS): an expert consensus project report
Background: Almost all large-scale trials of disease-modifying therapeutic agents in critical care have failed to show benefit for patients, which may be explained in part by the clinical and biological heterogeneity inherent in virtually all critical illness syndromes. Enrichment strategies have been developed to separate responders from non-responders and better target treatments. In patients with the acute respiratory distress syndrome, a critical illness syndrome involving severe lung inflammation, latent class analysis and other clustering approaches have led to the discovery of subgroups (phenotypes) that appear to respond differently to treatment based on retrospective analyses of published clinical trials and observational cohorts. The next step is to test these phenotypes in a prospective trial. Rapid, point-of-care analytical methods have now made such a trial possible. There is a need to advance treatment for patients with acute respiratory distress syndrome and other critical illness syndromes by incorporating a phenotype-based approach into prospective trial design. The hyperinflammatory and hypoinflammatory phenotypes, that have been identified in acute respiratory distress syndrome, will be the first to be included in such a trial, with scope for further phenotypes to be studied over time. Future work: This Efficacy and Mechanism Evaluation report, through expert consensus, describes a new Phase II, multiarm, adaptive platform randomised controlled trial design that tests multiple pharmacological therapies in a population of patients with acute respiratory distress syndrome stratified by baseline inflammatory phenotype. This report also reviews issues to be considered in developing precision medicine trials in critical care, which are designed with newly developed clinical phenotypes in mind. This work has been used to develop the Precision medicine Adaptive Network platform Trial in Hypoxaemic acutE respiratory failuRe precision medicine trial in acute respiratory distress syndrome, which has been funded and will begin recruitment in June 2025. Limitations: This report is the result of expert consensus review, rather than utilising strict review methodologies (e.g. Delphi consensus process). However, expert consensus has been found to generate similar results to consensus processes when a high degree of agreement is reached and > 70% agreement was reached for all included recommendations. Funding: This article presents independent research funded by the (NIHR) Efficacy and Mechanism Evaluation programme as award number NIHR154493.
- 1 July 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-43
Open AccessBuilding an international precision medicine platform trial for the acute respiratory distress syndrome (ARDS): an expert consensus project report
Background: Almost all large-scale trials of disease-modifying therapeutic agents in critical care have failed to show benefit for patients, which may be explained in part by the clinical and biological heterogeneity inherent in virtually all critical illness syndromes. Enrichment strategies have been developed to separate responders from non-responders and better target treatments. In patients with the acute respiratory distress syndrome, a critical illness syndrome involving severe lung inflammation, latent class analysis and other clustering approaches have led to the discovery of subgroups (phenotypes) that appear to respond differently to treatment based on retrospective analyses of published clinical trials and observational cohorts. The next step is to test these phenotypes in a prospective trial. Rapid, point-of-care analytical methods have now made such a trial possible. There is a need to advance treatment for patients with acute respiratory distress syndrome and other critical illness syndromes by incorporating a phenotype-based approach into prospective trial design. The hyperinflammatory and hypoinflammatory phenotypes, that have been identified in acute respiratory distress syndrome, will be the first to be included in such a trial, with scope for further phenotypes to be studied over time. Future work: This Efficacy and Mechanism Evaluation report, through expert consensus, describes a new Phase II, multiarm, adaptive platform randomised controlled trial design that tests multiple pharmacological therapies in a population of patients with acute respiratory distress syndrome stratified by baseline inflammatory phenotype. This report also reviews issues to be considered in developing precision medicine trials in critical care, which are designed with newly developed clinical phenotypes in mind. This work has been used to develop the Precision medicine Adaptive Network platform Trial in Hypoxaemic acutE respiratory failuRe precision medicine trial in acute respiratory distress syndrome, which has been funded and will begin recruitment in June 2025. Limitations: This report is the result of expert consensus review, rather than utilising strict review methodologies (e.g. Delphi consensus process). However, expert consensus has been found to generate similar results to consensus processes when a high degree of agreement is reached and > 70% agreement was reached for all included recommendations. Funding: This article presents independent research funded by the (NIHR) Efficacy and Mechanism Evaluation programme as award number NIHR154493.
- Open Access
Principal investigators’ experience of COVID-19 therapeutic clinical trials in Japan: a qualitative study
Objective: During the COVID-19 pandemic, many clinical trials were conducted to identify effective COVID-19 therapeutics. However, while a large amount of resources was invested and significant numbers of patients participated, this did not necessarily have an impact on clinical practice. To face these issues, initiatives such as the 100 Days Mission have been set out globally. Yet, limited data exist on the context surrounding the implementation of clinical trials at a national level during a health emergency. The study explored experiences and perceptions of principal investigators in conducting clinical trials for COVID-19 therapeutics in Japan. Design: A qualitative study was conducted using semistructured interviews. The obtained data were inductively analysed using thematic analysis. Setting and participants: We interviewed 15 principal investigators between September and November 2022 who conducted investigator-initiated clinical trials on the development of COVID-19 therapeutics in Japan. Results: Three themes were generated: structural barriers , fragmented efforts and limited evidence generation . Structural barriers and fragmented efforts comprised four subthemes: individual, institutional, interinstitutional and policy/regulatory levels. Structural barriers at all levels included (1) limitations of individual capabilities, (2) the double burden of clinical practice and research, (3) inefficient interinstitutional collaboration and (4) regulatory frameworks and available resources that interrupt stakeholders’ actions, leading to limited evidence generation despite the fragmented efforts of principal investigators and other stakeholders. Conclusions: This study illustrated that the efforts of Japanese principal investigators did not necessarily pay off in identifying therapeutics. A strategic and systematic approach for an improved national clinical trial ecosystem must be sought during the interpandemic period to overcome structural barriers in harmonisation with the global stakeholders.
Open AccessPrincipal investigators’ experience of COVID-19 therapeutic clinical trials in Japan: a qualitative study
Objective: During the COVID-19 pandemic, many clinical trials were conducted to identify effective COVID-19 therapeutics. However, while a large amount of resources was invested and significant numbers of patients participated, this did not necessarily have an impact on clinical practice. To face these issues, initiatives such as the 100 Days Mission have been set out globally. Yet, limited data exist on the context surrounding the implementation of clinical trials at a national level during a health emergency. The study explored experiences and perceptions of principal investigators in conducting clinical trials for COVID-19 therapeutics in Japan. Design: A qualitative study was conducted using semistructured interviews. The obtained data were inductively analysed using thematic analysis. Setting and participants: We interviewed 15 principal investigators between September and November 2022 who conducted investigator-initiated clinical trials on the development of COVID-19 therapeutics in Japan. Results: Three themes were generated: structural barriers , fragmented efforts and limited evidence generation . Structural barriers and fragmented efforts comprised four subthemes: individual, institutional, interinstitutional and policy/regulatory levels. Structural barriers at all levels included (1) limitations of individual capabilities, (2) the double burden of clinical practice and research, (3) inefficient interinstitutional collaboration and (4) regulatory frameworks and available resources that interrupt stakeholders’ actions, leading to limited evidence generation despite the fragmented efforts of principal investigators and other stakeholders. Conclusions: This study illustrated that the efforts of Japanese principal investigators did not necessarily pay off in identifying therapeutics. A strategic and systematic approach for an improved national clinical trial ecosystem must be sought during the interpandemic period to overcome structural barriers in harmonisation with the global stakeholders.
- Open Access
- 30 April 2025
- Published by National Center for Global Health and Medicine (JST) in Global Health & Medicine
- Vol. 7 (2) , 96-105
How to build a better clinical trial ecosystem for future infectious disease emergencies in Japan: Findings from a narrative review and stakeholder meetings
The COVID-19 pandemic posed a serious challenge to national and global pandemic preparedness and response (PPR). Timely identification and development of diagnostics, therapeutics and vaccines through prompt evidence generation from clinical trials was recognized as an important health security agenda. In 2022, under the guidance of Japan Ministry of Health, Labour and Welfare (MHLW), a health policy research team was convened to analyze the COVID-19 related clinical trial ecosystem in the context of PPR in Japan and abroad with a focus on clinical trials for therapeutics. The research mainly composed of the following: a narrative review of relevant peer reviewed journals and grey literature, interview of global experts and stakeholders including those from the United States and the United Kingdom, and a culminating meeting in Japan with various stakeholders. Based on the outcomes of this research, the team makes the following three recommendations: (1) Strengthen the leadership group's role in infectious disease clinical trials, (2) Promote sustained coordination and collaboration among stakeholders, and (3) Apply innovative clinical trial designs and create an enabling research environment. Clinical trials, as a public health good, must be further integrated into healthcare. The team advocates for the implementation of these recommendations at the policy level to help improve the clinical trial ecosystem for future health emergencies in Japan.
- 30 April 2025
- Published by National Center for Global Health and Medicine (JST) in Global Health & Medicine
- Vol. 7 (2) , 96-105
Open AccessHow to build a better clinical trial ecosystem for future infectious disease emergencies in Japan: Findings from a narrative review and stakeholder meetings
The COVID-19 pandemic posed a serious challenge to national and global pandemic preparedness and response (PPR). Timely identification and development of diagnostics, therapeutics and vaccines through prompt evidence generation from clinical trials was recognized as an important health security agenda. In 2022, under the guidance of Japan Ministry of Health, Labour and Welfare (MHLW), a health policy research team was convened to analyze the COVID-19 related clinical trial ecosystem in the context of PPR in Japan and abroad with a focus on clinical trials for therapeutics. The research mainly composed of the following: a narrative review of relevant peer reviewed journals and grey literature, interview of global experts and stakeholders including those from the United States and the United Kingdom, and a culminating meeting in Japan with various stakeholders. Based on the outcomes of this research, the team makes the following three recommendations: (1) Strengthen the leadership group's role in infectious disease clinical trials, (2) Promote sustained coordination and collaboration among stakeholders, and (3) Apply innovative clinical trial designs and create an enabling research environment. Clinical trials, as a public health good, must be further integrated into healthcare. The team advocates for the implementation of these recommendations at the policy level to help improve the clinical trial ecosystem for future health emergencies in Japan.
- Open Access
- 1 January 2025
- Published by Wiley in Acute Medicine & Surgery
- Vol. 12 (1) , e70045
Sepsis in Global Health: Current global strategies to fight against sepsis
Sepsis is prevalent globally, causing a significant disease burden in global health. Sepsis is a complex disease condition, and therefore, the effective strategies to overcome sepsis need to be set up in layers across different sectors and populations. Over the years, the global society has been making progress in addressing sepsis as a public health threat. This review aims to examine and describe the current sepsis strategies globally and to sustain the fight against sepsis in the context of global health.
- 1 January 2025
- Published by Wiley in Acute Medicine & Surgery
- Vol. 12 (1) , e70045
Open AccessSepsis in Global Health: Current global strategies to fight against sepsis
Sepsis is prevalent globally, causing a significant disease burden in global health. Sepsis is a complex disease condition, and therefore, the effective strategies to overcome sepsis need to be set up in layers across different sectors and populations. Over the years, the global society has been making progress in addressing sepsis as a public health threat. This review aims to examine and describe the current sepsis strategies globally and to sustain the fight against sepsis in the context of global health.
- Open Access
- 11 November 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 46 (1) , 35-42
Transmission of MRSA, ESBL E. coli, and C. difficile within a tertiary care hospital and across surrounding facilities in Japan: a molecular epidemiological study with the PCR-based Open-reading frame typing
Objective: To determine the regional impact of transmission of multidrug-resistant organisms (MRDOs) and Clostridioides difficile (C. difficile) among a tertiary care hospital and surrounding facilities including long-term care facilities (LTCFs).Design: Retrospective cohort study.Methods: Patients admitted to a tertiary care hospital from July 2019 to July 2021 were recruited if their clinically collected cultures grew the following pathogens: Methicillin-resistant Staphylococcus aureus (MRSA), Extended-Spectrum Beta-Lactamase (ESBL) producing Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, Carbapenem-resistant Enterobaterales, Vancomycin-resistant Enterococci, and C. difficile. Patient characteristics including admission and discharge pathway were collected. For the isolates of MRSA, ESBL-producing Escherichia coli (E. coli), and C. difficile, a molecular epidemiological analysis was conducted, utilizing the PCR-based Open-Reading Frame Typing (POT) method.Results: Three hundred-five patients were identified with a total of 332 culture specimens of the target pathogens. The top three were 132 MRSA isolates (43.3%, out of 305), 97 ESBL E. coli (31.8%), and 32 ESBL Enterobacterales (non-E. coli) (10.5%). The target pathogens were more detectable within 3 days among patients admitted from LTCFs or other hospitals than those admitted from home (Odds Ratio 4.6, 95% confidence interval 2.8-7.6, p-value < 0.001). The molecular epidemiological analysis suggested the transmissions of MRSA, ESBL E. coli and C. difficile occurred 52 out of 111 patients within the in-hospital environment, and 7 out of 128 within the prehospital environment, respectively.Conclusions: MDROs/C. difficile transmission is prevalent within a tertiary care hospital and further complicated by its inter-facility transmission across surrounding LTCFs and hospitals in Japan.
- 11 November 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 46 (1) , 35-42
Open AccessTransmission of MRSA, ESBL E. coli, and C. difficile within a tertiary care hospital and across surrounding facilities in Japan: a molecular epidemiological study with the PCR-based Open-reading frame typing
Objective: To determine the regional impact of transmission of multidrug-resistant organisms (MRDOs) and Clostridioides difficile (C. difficile) among a tertiary care hospital and surrounding facilities including long-term care facilities (LTCFs).Design: Retrospective cohort study.Methods: Patients admitted to a tertiary care hospital from July 2019 to July 2021 were recruited if their clinically collected cultures grew the following pathogens: Methicillin-resistant Staphylococcus aureus (MRSA), Extended-Spectrum Beta-Lactamase (ESBL) producing Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, Carbapenem-resistant Enterobaterales, Vancomycin-resistant Enterococci, and C. difficile. Patient characteristics including admission and discharge pathway were collected. For the isolates of MRSA, ESBL-producing Escherichia coli (E. coli), and C. difficile, a molecular epidemiological analysis was conducted, utilizing the PCR-based Open-Reading Frame Typing (POT) method.Results: Three hundred-five patients were identified with a total of 332 culture specimens of the target pathogens. The top three were 132 MRSA isolates (43.3%, out of 305), 97 ESBL E. coli (31.8%), and 32 ESBL Enterobacterales (non-E. coli) (10.5%). The target pathogens were more detectable within 3 days among patients admitted from LTCFs or other hospitals than those admitted from home (Odds Ratio 4.6, 95% confidence interval 2.8-7.6, p-value < 0.001). The molecular epidemiological analysis suggested the transmissions of MRSA, ESBL E. coli and C. difficile occurred 52 out of 111 patients within the in-hospital environment, and 7 out of 128 within the prehospital environment, respectively.Conclusions: MDROs/C. difficile transmission is prevalent within a tertiary care hospital and further complicated by its inter-facility transmission across surrounding LTCFs and hospitals in Japan.